The USFDA inspected the company's transdermal patch manufacturing facility in Pharmez, Ahmedabad, from 15th to 19th July 2024, and has classified it as 'voluntary action indicated' (VAI) after issuing an Establishment Inspection Report (EIR). In August, the FDA issued a warning letter to the company's drug manufacturing facility in Jarod, Gujarat, citing inadequate Current Good Manufacturing Practices (CGMP). The inspection in April 2024 revealed issues related to cross-contamination, particulate contamination, and poor aseptic procedures. As of 30th June 2024, the company has received 400 approvals and has filed over 465 ANDAs (Abbreviated New Drug Applications) since starting the filing process in FY 2003-04. At 3:30 PM, the shares of Zydus Lifesciences closed 0.74% higher at Rs 1,064.80 on NSE. Ready to invest like a pro?